Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14476 - 14500 of 15239 in total
Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Experimental
Experimental
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Experimental
Experimental
Investigational
MK-4965 is an HIV-1 reverse transcriptase inhibitor.
Experimental
Evatanepag has been used in trials studying the treatment of Tibial Fractures.
Investigational
Iguratimod is under investigation in Rheumatoid Arthritis.
Investigational
Experimental
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and
Displaying drugs 14476 - 14500 of 15239 in total